



## Key Collaborations

Bayer has established a broad cooperative research network with healthcare professionals, academic research centers, other pharmaceutical companies and innovative biotech organizations worldwide. Together with these partners, we have helped usher in the company's first generation of cancer therapies, and together, we are helping to pave the way for future development. The ongoing expansion of this network fosters an open exchange of ideas and helps expand Bayer's vision of treatment for cancer patients. Examples of Bayer's collaborations include:

### **German Cancer Research Center (DKFZ):**

Collaboration established in 2009 and 2013, and which was expanded to include a joint immune-therapeutics lab. Scientists from both networks work together in a joint laboratory located at the National Center for Tumor Diseases (NCT) in Heidelberg, Germany.

**Broad Institute:** A ten-year strategic alliance that pairs Broad's expertise in cancer genomics, chemical biology and drug discovery with Bayer's in-depth experience in small, chemically manufactured molecules and pharmaceutical development.

### **Structural Genomics**

**Consortium (SGC):** Bayer has joined SGC to support funding, provide a subset of its compound library for screening to the SGC and conduct the chemical work to identify probes.

## References


1. GLOBOCAN. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. All Cancers (excluding non-melanoma skin cancer) Estimated Incidence, Mortality and Prevalence Worldwide in 2012. [http://globocan.iarc.fr/Pages/fact\\_sheets\\_cancer.aspx](http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx). Accessed July 2018.
2. Jones, C. L., & Kane, M. A. (1996). Oncogenic signaling. *Current Opinion in ONCOLOGY*,8(1), 54-59.doi:10.1097/00001622-199601000-00010. Accessed July 2018.
3. National Cancer Institute. Signaling Pathway. <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/signaling-pathway>. Accessed July 2018.
4. American Cancer Society. What is cancer immunotherapy. <http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/immunotherapy/immunotherapy-what-is-immunotherapy>. Accessed July 2018.
5. Dekempeneer Y et al. *Expert Opin Biol Ther* 2016;16:1035–1047. 2. Suominen MI et al. *Clin Cancer Res* 2017;23:4335–4346. Accessed July 2018.
6. World Health Organization. Cancer. <http://www.who.int/mediacentre/factsheets/fs297/en/>. Accessed July 2018.

# Oncology Inspired Bayer in Oncology



Unmet  
needs exist...

Cancer can  
*grow  
and change*  
over time



There are nearly **100** different types of cancer increase in cancer incidence is expected by 2030<sup>6</sup>

### Bayer in Oncology

Over the last 20 years, the cancer treatment landscape has seen significant progress. However, there is still much work to be done to help the more than 33 million people living with cancer across the globe.<sup>1</sup> Bayer is committed to transforming the lives of people impacted by cancer, with **a curative resolve** fueled by science and innovation.

### Oncology Research Platforms

In just over a decade, the advancing oncology portfolio at Bayer has expanded significantly. Our oncology research prioritizes cutting-edge science across a range of therapeutic platforms:

- // **Oncogenic Signaling:** Blocking signaling pathways that can cause cancer to grow and spread.<sup>2,3</sup>
- // **Immuno-Oncology:** Harnessing the power of the immune system to fight cancer cells, with novel checkpoint targets developed alongside corresponding monoclonal antibodies and small molecules.<sup>4</sup>
- // **Targeted Thorium Conjugates:** Delivering systemic high-energy alpha-particle radiation to cancer cells and the tumor microenvironment.<sup>5</sup>

### Commitment to Research and Innovation

Cancer is a particularly complex disease, and there is no “silver bullet” when it comes to treatment. With this in mind, Bayer is taking a focused approach to the research and development driving our next wave of innovation while we work to maximize existing treatments, in an effort to broaden our impact on patients in need while continuing to serve the patients we have. Together with our partners, we remain focused on driving cutting-edge science, ensuring benefit to patients and remaining a partner of choice.



### A Patient-Centered Approach

We are driven every day by what matters most to the cancer community, and work hard to offer meaningful progress to healthcare professionals and patients battling the toughest cancers with high unmet medical needs.

Patient-reported outcomes are an important efficacy measure in our trials, and real patient feedback informs the design and implementation of new clinical trials.



### Stronger Together

At Bayer, we have the passion, dedication and determination to research and develop innovative medicines to help improve the outcomes for patients battling the toughest cancers.

We joined forces to keep on pushing with industry partners and the European Federation of Pharmaceutical Industries and Associations (EFPIA) in pledging that #WeWontRest in the fight against cancer. Furthermore, together with the Pharmaceutical Research and Manufacturers of America (PhRMA), we reach out to inform legislators and policy-makers that we need to #GoBoldly in precision medicine to treat cancer patients.